NCT01848054 - Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence | Biotech Hunter

Enrollment

313

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Opioid-Related DisordersOpiate Dependence

Interventions

DRUG

Buprenorphine/naloxone sublingual tablets

Advanced-formulation buprenorphine/naloxone sublingual tablets

DRUG

Buprenorphine

Buprenorphine sublingual tablets

Trial Locations (14)

Birmingham

Haleyville

National City

Oceanside

Jacksonville

Maitland

North Miami

Baltimore

Fall River

Flowood

Philadelphia

Charleston

Houston

Salt Lake City